Abstracts tagged "glucocorticoids and tocilizumab"

Abstract Number: 844 • 2019 ACR/ARP Annual Meeting
Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial
Frank Buttgereit¹, Gerd Burmester ², J. Michael Nebesky ³, Jenny Devenport ³, Marc Y. Donath ⁴ and Markus R. John ³, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité—University Medicine Berlin, Berlin, Germany, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴University Hospital Basel, Basel, Switzerland
Background/Purpose: Glucocorticoids (GCs) directly impact bone metabolism via increased bone resorption and inhibited bone formation1; hence, systemic fracture risk increases with daily and cumulative GC…
Abstract Number: 1383 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study
Frank Buttgereit¹, J. Michael Nebesky ², Gerd Burmester ³, Corrado Bernasconi ², Markus R. John ² and Marc Y. Donath ⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴University Hospital Basel, Basel, Switzerland
Background/Purpose: Systemic glucocorticoids (GCs) are used to treat serious inflammatory diseases but are associated with adverse events. Guidelines recommend tapering GCs to the lowest possible…
Abstract Number: 3183 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Stephan Reichenbach^1,2, Sabine Adler³, Jennifer Cullmann⁴, Harald Bonel⁴, Stefan Kuchen⁵, Felix Wermelinger¹, Diana Dan¹, Michael Seitz¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ⁴Department of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].